Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: A meta-analysis

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 6, 2007, Pages 1216-1226

  Ioannidou, Eleni ^a   Siempos, Ilias I ^a   Falagas, Matthew E ^a,b,c  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Healthcare associated pneumonia; ICU acquired pneumonia; Respiratory tract infections; Ventilator associated pneumonia

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CARBENICILLIN; CEFAZOLIN; CILASTATIN PLUS IMIPENEM; GENTAMICIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; SISOMICIN; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL PNEUMONIA; BRONCHOPNEUMONIA; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; DRUG WITHDRAWAL; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; MEDLINE; META ANALYSIS; NEBULIZER; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; REVIEW; SCISEARCH; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; URINARY CAST; VENTILATOR ASSOCIATED PNEUMONIA;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; CROSS INFECTION; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INTENSIVE CARE UNITS; PNEUMONIA; PNEUMONIA, VENTILATOR-ASSOCIATED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY SYSTEM; TREATMENT OUTCOME;

EID: 36448980984     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm385     Document Type: Review

References (45)

1. Koulenti D, Rello J. Hospital-acquired pneumonia in the 21st century: A review of existing treatment options and their impact on patient care. Expert Opin Pharmacother 2006; 7: 1555-69.
2. Scheetz MH, Wunderink RG, Postelnick MJ et al. Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia. Pharmacotherapy 2006; 26: 539-50.
3. Wenzel RP. The antibiotic pipeline-challenges, costs and values. N Engl J Med 2004; 351: 523-6.
4. Lesho E. Role of inhaled antibacterials in hospital-acquired and ventilator-associated pneumonia. Expert Rev Anti Infect Ther 2005; 3: 445-51.
5. Dessanges JF. A history of nebulization. J Aerosol Med 2001; 14 65-71.
6. Conway SP. Nebulized antibiotic therapy: The evidence. Chron Respir Dis 2005; 2: 35-41.
7. Falagas ME, Siempos II, Bliziotis IA et al. Administration of antibiotics via the respiratory tract for the prevention of ICU-acquired pneumonia: A meta-analysis of comparative trials. Crit Care 2006; 10: R123.
8. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
9. http://www.cochrane.org/resources/handbook/Handbook/ Handbook4.2.6.Sep2006.pdf Pages 81, 137-8. (5 September 2007, date last accessed).
10. Higgins JP, Thompson SG, Deeks JJ et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
11. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22 719-48.
12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
13. Hallal A, Cohn SM, Namias N et al. Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: A pilot study. Surg Infect (Larchmt) 2007; 8: 73-82.
14. Le Conte P, Potel G, Clementi E et al. Administration of tobramycin aerosols in patients with nosocomial pneumonia: A preliminary study. Presse Med 2000; 29: 76-8.
15. Brown RB, Kruse JA, Counts GW et al. Double-blind study of endotracheal tobramycin in the treatment of gram-negative bacterial pneumonia. The Endotracheal Tobramycin Study Group. Antimicrob Agents Chemother 1990; 34: 269-72.
16. Klastersky J, Carpentier-Meunier F, Kahan-Coppens L et al. Endotracheally administered antibiotics for gram-negative broncho-pneumonia. Chest 1979; 75: 586-91.
17. Klastersky J, Geuning C, Mouawad E et al. Endotracheal gentamicin in bronchial infections in patients with tracheostomy. Chest 1972; 61: 117-20.
18. Wood GC, Swanson JM. Aerosolised antibacterials for the prevention and treatment of hospital-acquired pneumonia. Drugs 2007; 67: 903-14.
19. Hamer DH. Treatment of nosocomial pneumonia and tracheo-bronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med 2000; 162: 328-30.
20. Sorensen VJ, Horst HM, Obeid FN et al. Endotracheal aminoglycosides in gram negative pneumonia. A preliminary report. Am Surg 1986; 52: 391-4.
21. Pines A, Raafat H, Siddiqui GM et al. Treatment of severe Pseudomonas infections of the bronchi. BMJ 1970; 1: 663-5.
22. Michalopoulos A, Kasialkou SK, Mastora Z et al. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005; 9: R53-9.
23. Kwa AL, Loh C, Low JG et al. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2005; 41: 754-7.
24. Stoutenbeek CP, van Saene HK, Miranda DR et al. Nosocomial gram-negative pneumonia in critically ill patients. A 3-year experience with a novel therapeutic regimen. Intensive Care Med 1986; 12 419-23.
25. Pines A, Raafat H, Plucinski K. Gentamicin and colistin in chronic purulent bronchial infections. BMJ 1967; 2: 543-5.
26. Horianopoulou M, Lambropoulos S, Papafragas E et al. Effect of aerosolized colistin on multidrug-resistant Pseudomonas aeruginosa inbronchial secretions of patients without cystic fibrosis. J Chemother 2005; 17: 536-8.
27. Berlana D, Llop JM, Fort E et al. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. Am J Health Syst Pharm 2005; 62: 39-47.
28. Canton R, Cobos N, de Gracia J et al., on behalf of the Spanish Consensus Group for Antimicrobial Therapy in the Cystic Fibrosis Patient. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin Microbiol Infect 2005; 11: 690-703.
29. Wood DM, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2006; 25: CD004197.
30. Le Conte P, Potel G, Peltier P et al. Lung distribution and pharmacokinetics of aerosolized tobramycin. Am Rev Respir Dis 1993; 147: 1279-82.
31. Odio W, Van Laer E, Klastersky J. Concentrations of gentamicin in bronchial secretions after intramuscular and endotracheal administration. J Clin Pharmacol 1975; 15: 518-2435.
32. MacIntyre NR, Rubin BK. Should aerosolized antibiotics be administered to prevent or treat ventilator-associated pneumonia in patients who do not have cystic fibrosis? Respir Care 2007; 52: 416-21; discussion 421-2.
33. Lesho E. Role of inhaled antibacterials in hospital-acquired and ventilator-associated pneumonia. Expert Rev Anti Infect Ther 2005; 3: 445-51.
34. Miller DD, Amin MM, Palmer LB et al. Aerosol delivery and modern mechanical ventilation: in vitrol in vivo evaluation. Am J Respir Crit Care Med 2003; 168: 1205-9.
35. Feeley TW, Du Moulin GC, Hadley-Whyte J et al. Aerosol polymyxin and pneumonia in seriously ill patients. N Engl J Med 1975; 293 471-5.
36. Klastersky J, Huysmans E, Weerts D et al. Endotracheally administered gentamicin for the prevention of infections of the respiratory tract in patients with tracheostomy: A double-blind study. Chest 1974; 65: 650-4.
37. Smith AL. Inhaled antibiotic therapy: What drug? What dose? What regimen? What formulation? J Cyst Fibros 2002; 1 Suppl 2: 189-93.
38. Ramsey BW, Pepe MS, Quan JM et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340: 23-30.
39. Falagas ME, Kasiakou SK. Local administration of polymyxins into the respiratory tract for the prevention and treatment of pulmonary infections in patients without cystic fibrosis. Infection 2007; 35: 3-10.
40. Michalopoulos A, Kasiakou SK, Falagas ME. The significance of different formulations of aerosolized colistin. Crit Care 2005; 9: 417-8.
41. Alothman GA, Ho B, Alsaadi MM et al. Bronchial constriction and inhaled colistin in cystic fibrosis. Chest 2005; 127: 522-9.
42. Kahler DA, Schowengerdt KO, Fricker FJ et al. Toxic serum trough concentrations after administration of nebulized tobramycin. Pharmacotherapy 2003; 23: 543-5.
43. Hoffmann IM, Rubin BK, Iskandar SS et al. Acute renal failure in cystic fibrosis: Association with inhaled tobramycin therapy. Pediatr Pulmonol 2002; 34: 375-7.
44. Steme JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: Power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000; 53: 1119-29.
45. Ioannidis JP, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in meta-analyses: A large survey. CMAJ 2007; 176: 1091-6.